Open Beta
TREN
MetriLume
TREN

US marketsALNY

SEC-sourced researchBeta

ALNY

ALNYLAM PHARMACEUTICALS, INC.

Company comparison ↗

Data passport

CIK
0001178670
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 6, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 1,828,292,000.0000 USD; December 2024: 2,248,243,000.0000 USD; December 2025: 3,713,937,000.0000 USD3.7B USD0 USD0December 2023December 2024December 2025
ALNY · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20231,828,292,000.0000Feb 12, 2026
December 20242,248,243,000.0000Feb 12, 2026
December 20253,713,937,000.0000Feb 12, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20253,713,937,000.0000313,747,000.0000524,080,000.00004,966,331,000.00004,177,155,000.0000Feb 12, 2026
December 20242,248,243,000.0000-278,157,000.0000-8,312,000.00004,239,983,000.00004,172,895,000.0000Feb 12, 2026
December 20231,828,292,000.0000-440,242,000.0000104,156,000.0000——Feb 12, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

72/100
Profitability67
Growth100
Balance sheet16
Cash generation78
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$3.71BJan 1, 2025 – Dec 31, 2025Feb 12, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$2.25BJan 1, 2024 – Dec 31, 2024Feb 12, 202610-K
Net incomeNetIncomeLoss$313.75MJan 1, 2025 – Dec 31, 2025Feb 12, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$524.08MJan 1, 2025 – Dec 31, 2025Feb 12, 202610-K
Total assetsAssets$4.97BDec 31, 2025Feb 12, 202610-K
Total liabilitiesLiabilities$4.18BDec 31, 2025Feb 12, 202610-K

New filings

Explore methodology ↗